Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

GlaxoSmithKline PLC Add to portfolio

LON100:GSK, Feb 27, 11:42 UTC

Latest LON100:GSK News

Filter your feed

Apply Filter

Thursday, February 20


News

The Zacks Analyst Blog Highlights: Facebook, Netflix, NextEra Energy, GlaxoSmithKline and T-Mobile US

GSK GSK +4 more GSK GSK TMUS FB NEE NFLX

Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Facebook FB, Netflix NFLX, NextEra Energy NEE, GlaxoSmithKline GSK and T-Mobile US TMUS. Today's Research Daily features new research reports on 16 major stocks, including Facebook, Netflix and NextEra Energy. The Zacks analyst believes that Netflix is expected to benefit from an expanding content portfolio despite increasing competition from the likes of HBO, Amazon prime video, Disney+ and Apple TV+.

Read Full Details

Topics:
  • Business
  • Financial

Sunday, February 16


News

Better Buy: GlaxoSmithKline vs. Bristol-Myers Squibb

GSK GSK +2 more GSK GSK BMY BIIB

In fact, every single big pharma company outperformed the broader biopharmaceutical industry during this period in terms of total returns on capital, including dividends and assuming a dividend reinvestment plan. The top dogs in the industry have crushed the broader markets over the past-half decade as the result of major structural changes to their internal operations, as well as a stronger focus on developing truly innovative new products for cancer, rare diseases, and infectious diseases. Bristol, on the other hand, recently bulked up by acquiring top cancer and immunology specialist Celgene. So with these two big pharmas entering a new phase in their respective life cycles, it's arguably the perfect time to consider which stock has the better long-term prospects. That's an encouraging development following Glaxo's less-than-stellar showing in the prior decade, a rather dark period in the company's history characterized by bribery scandals, numerous clinical failures, and an inability to move the investing narrative beyond the eventual decline of megablockbuster respiratory medicine Advair. What's the next step? While Pfizer and Glaxo have yet to agree on a timeline for the official launch of their consumer healthcare business as a standalone unit, this seminal event should take place by no later than 2024. As part of this seismic shift in the company's underlying business, Glaxo plans on continuing to divest certain noncore assets to both offset the costs associated with this upcoming consumer healthcare spinoff, and presumably to assuage regulators in the U.S. and EU. As a direct consequence of this spinoff, Glaxo seems poised to remain fairly dormant on the merger-and-acquisition scene over the next few years.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Thursday, February 13


News

Global Anti-Thyroid Drugs Market Research Report 2020 - Mylan, Abbott Labs, GlaxoSmithKline, Merck, and AbbVie are Dominating

GSK GSK +3 more GSK GSK MRK MYL ABBV

The global anti-thyroid drugs market was valued at about $2.46 billion in 2018 and is expected to grow to $2.79 billion at a CAGR of 3.2% through 2022. Major players in the market are Mylan N.V., Abbott Laboratories, GlaxoSmithKline plc, Merck & Co. and AbbVie, Inc.The anti-thyroid drugs market has been geographically segmented into North America, Western Europe, APAC, Eastern Europe, South America and Middle East & Africa. There are many side effects associated with the medication used to treat hyperthyroidism. For instance, according to a study it was found that two most commonly used anti-thyroid medications propylthiouracil (PTU) and methimazole (MMI) causes hepatotoxicity and death in children and major abnormalities in the fetus.Associations for thyroid care are launching initiatives to spread more awareness about thyroid disorders, update on the recent treatment methods and other summaries regarding various research on thyroid disorders. Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
  • Entertainment

Friday, February 07


News

Pharma Stock Roundup: BMY, GSK, SNY Q4 Results, MRK Earnings & Split

SAN GSK +3 more SAN GSK BMY MRK ABBV

In 2020, Merck expects revenues to be in the range of $48.8 billion – $50.3 billion, while earnings are expected to be in the range of $5.62–$5.77. For Sanofi, double-digit growth in the Specialty Care and Vaccines was offset by persistent sluggishness in Diabetes and Cardiovascular franchises and a weak performance in the Consumer HealthCare unit in the quarter. Pharmaceuticals segment sales were down 4% at CER as the company’s established drugs continued to decline. However, the company’s new products from every segment performed well in the reported quarter, especially Shingrix. Merck to Separate Into Two Companies: Along with the earnings release, Merck revealed plans to spin off its women's healthcare unit, biosimilar drugs and legacy products into an independent public company. Click to get this free report Sanofi (SNY) : Free Stock Analysis Report Novo Nordisk A/S (NVO) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Merck & Co., Inc. (MRK) : Free Stock Analysis Report Bristol-Myers Squibb Company (BMY) : Free Stock Analysis Report GlaxoSmithKline plc (GSK) : Free Stock Analysis Report To read this article on Zacks.com click here.

Read Full Details

Topics:
  • Business
  • Health

Thursday, February 06


News

GlaxoSmithKline Cutting Up to 720 Jobs at European Vaccine Facility

GSK GSK

GlaxoSmithKline Cutting Up to 720 Jobs at European Vaccine Facility | NASDAQ. In advance of its split into two companies, pharmaceutical giant GlaxoSmithKline(NYSE: GSK) announced it will cut as many as 720 workers from its vaccine production facility in Belgium. In addition to these layoffs, which are part of its two-year restructuring program, the company said it will decline to renew the contracts of 215 temporary employees. It has been a high-growth segment for GlaxoSmithKline lately, thanks mainly to its next-generation shingles vaccine Shingrix (responsible for around $2.3 billion in sales in the company's fiscal 2019 -- more than double the 2018 result).

Read Full Details

Story Sources

nasdaq.com fool.com
Topics:
  • Business
  • Health
  • Financial
News

Break-up of Glaxosmithkline will cost £2.4bn

GSK GSK

We have noticed that there is an issue with your subscription billing details. The subscription details associated with this account need to be updated. Please update your billing details here to continue enjoying your access to the most informative and considered journalism in the UK. The FTSE 100 company yesterday issued details of its ambitious plans to spin-off its consumer healthcare joint venture with Pfizer via a listing on the London Stock Exchange in 2022.

Read Full Details

Topics:
  • Business
  • Financial
  • Health

Wednesday, February 05


News

GlaxoSmithKline Predicts a 2020 Loss, Prepares for Its Consumer Spinoff

GSK GSK

GlaxoSmithKline Predicts a 2020 Loss, Prepares for Its Consumer Spinoff | NASDAQ. GlaxoSmithKline(NYSE: GSK) reported fourth-quarter earnings results Wednesday, along with guidance for 2020 that was less than encouraging. But investors' disappointment with outlook may have been tempered somewhat by the accompanying news about the company's plan to completely spin off its consumer healthcare assets. During the last three months of 2019, GlaxoSmithKline earned an adjusted $0.33 per share which was $0.27 a share less than analysts' consensus estimate. Image source: Getty Images. For the year, sales of the company's next-generation shingles vaccine more than doubled to $2.34 billion, but investors should probably brace themselves for stagnating sales on that front once most older adults have received the vaccine. While vaccine sales exploded in 2019, the company's HIV segment grew by just 1% on a constant-currency basis.

Read Full Details

Story Sources

nasdaq.com fool.com
Topics:
  • Business
  • Health
  • Financial
News

GSK demerger carries risks as it pegs future to R&D progress

GSK

One will be New GSK, described as "a biopharma company with an R&D approach focused on science related to the immune system, use of genetics and new technologies". The other will comprise GSK's consumer healthcare business, owner of brands such as Aquafresh, Nicorette, Panadol and Zovirax, which will effectively be spun off. Ms Walmsley added: "This new two year programme aims to use the unique catalyst of separation to reset the capabilities and cost base for both companies and help deliver the significant value creation opportunities we see in both New GSK and New Consumer Healthcare." She poached Luke Miels from rival AstraZeneca to head GSK's global pharmaceutical business and also lured Hal Barron, the former chief medical officer at Swiss drugs giant Roche, away from a lucrative job in Silicon Valley to become GSK's chief scientific officer and head of R&D. Yet Wednesday's full year results also confirm that, while Ms Walmsley has been prepared to make bold decisions, it takes a long time in this industry for changes to show up in results.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
News

GSK profit falls short as cheap competition hits older drugs

GSK

GSK profit falls short as cheap competition hits older drugs. (Reuters) - GlaxoSmithKline missed fourth-quarter earnings forecasts on Wednesday as cheap competition to the British drugmaker's respiratory medicines offset strong growth in sales of its shingles vaccine. GSK shares fell as much as 3% after the company also said adjusted earnings for this year could fall as much as 4%. Under Chief Executive Emma Walmsley, the London-listed firm has sold several assets, and bought others in fast-growing markets such as oncology, to try to rejuvenate growth as several of its older drugs face losing patent protection.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Thursday, January 30


News

United States' $9 Billion Pneumonia Vaccine Industry, 2020-2026 - Major Players are Merck, Pfizer, GlaxoSmithKline (GSK), LG Chem, and SK Chemical (Sanofi Pasteur)

PFE GSK

Key trends in terms of collaboration deals, licensing agreement and partnership deals are analysed with details. The report also examines the main market growth driving and restraining forces and also gives an all-round future outlook through 2026.The report also provides comprehensive profiles of the dominant players in the country's pneumonia vaccines market such as Pfizer and Merck with important details on companies' vaccines portfolio and the latest developments. Other emerging players such as GlaxoSmithKline (GSK), LG Chem, and SK Chemical (Sanofi Pasteur) are making novel technology-based pneumonia vaccines that are likely to affect the market share during the forecast period.The Major Companies Dominating this Market for its Products, Services, and Continuous Product Developments are:. United States Pneumonia Vaccines Market Assessment & Opportunity (Value), 2015 - 20263.1 Prevnar / Prevnar 133.2 Pneumovax 233.3 V1143.4 PF-064820773.5 GSK34.

Read Full Details

Topics:
  • Business
  • Health
  • Financial